Add-on-statin extended release nicotinic acid/laropiprant but not the switch to high-dose rosuvastatin lowers blood pressure: An open-label randomized study

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Kei, Anastazia ^a   Elisaf, Moses ^a   Moutzouri, Elisavet ^a   Tsiara, Stavroula ^a   Liberopoulos, Evangelos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; INSULIN; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RELEASE; EXTENDED DRUG RELEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOLIPEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862862264     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/830434     Document Type: Article

References (34)

1. Goode G. K., Miller J. P., Heagerty A. M., Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 1995 345 8946 362 364 2-s2.0-0028813466
2. Halperin R. O., Sesso H. D., Ma J., Buring J. E., Stampfer M. J., Gaziano J. M., Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006 47 1 45 50 2-s2.0-31744432529 10.1161/01.HYP.0000196306.42418.0e (Pubitemid 43177814)
3. Williams R. R., Hunt S. C., Hopkins P. N., Stults B. M., Wu L. L., Hasstedt S. J., Barlow G. K., Stephenson S. H., Lalouel J. M., Kuida H., Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12 of patients with essential hypertension. Journal of the American Medical Association 1988 259 24 3579 3586 2-s2.0-0023890074
4. Baigent C., Blackwell L., Emberson J., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 376 1670 1681
5. Ferrier K. E., Muhlmann M. H., Baguet J. P., Cameron J. D., Jennings G. L., Dart A. M., Kingwell B. A., Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. Journal of the American College of Cardiology 2002 39 6 1020 1025 2-s2.0-0037139284 10.1016/S0735-1097(02)01717-5 (Pubitemid 34234125)
6. Pelat M., Dessy C., Massion P., Desager J. P., Feron O., Balligand J. L., Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E mice in vivo. Circulation 2003 107 19 2480 2486 2-s2.0-0038179586 10.1161/01.CIR.0000065601. 83526.3E (Pubitemid 36605232)
7. Sicard P., Delemasure S., Korandji C., Grand A. S. L., Lauzier B., Guilland J. C., Duvillard L., Zeller M., Cottin Y., Vergely C., Rochette L., Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radical Research 2008 42 3 226 236 2-s2.0-41049113282 10.1080/10715760701885380 (Pubitemid 351419909)
8. Ramesh Prasad G. V., Ahmed A., Nash M. M., Zaltzman J. S., Blood pressure reduction with HMG-COA reductase inhibitors in renal transplant recipients. Kidney International 2003 63 1 360 364 2-s2.0-0037213736 10.1046/j.1523-1755. 2003.00742.x (Pubitemid 35463942)
9. Terzoli L., Mircoli L., Raco R., Ferrari A. U., Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. Journal of Cardiovascular Pharmacology 2005 46 3 310 315 2-s2.0-24344440634 10.1097/01.fjc.0000175432.56789.e6 (Pubitemid 41262833)
10. Desjardins F., Sekkali B., Verreth W., Pelat M., De Keyzer D., Mertens A., Smith G., Herregods M. C., Holvoet P., Balligand J. L., Rosuvastatin increases vascular endothelial PPAR γ expression and corrects blood pressure variability in obese dyslipidaemic mice. European Heart Journal 2008 29 1 128 137 2-s2.0-37849040502 10.1093/eurheartj/ehm540
11. Carlson L. A., Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 2005 258 2 94 114 2-s2.0-22644437126 10.1111/j.1365-2796.2005.01528.x (Pubitemid 41025967)
12. Bays H. E., Rader D. J., Does nicotinic acid (niacin) lower blood pressure? International Journal of Clinical Practice 2009 63 1 151 159 2-s2.0-57649202648 10.1111/j.1742-1241.2008.01934.x
13. TREDAPTIVE product overview, 2011
14. Maccubbin D., Bays H. E., Olsson A. G., Elinoff V., Elis A., Mitchel Y., Sirah W., Betteridge A., Reyes R., Yu Q., Kuznetsova O., Sisk C. M., Pasternak R. C., Paolini J. F., Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. International Journal of Clinical Practice 2008 62 12 1959 1970 2-s2.0-53149118030 10.1111/j.1742-1241.2008.01938. x
15. Bays H. E., Maccubbin D., Meehan A. G., Kuznetsova O., Mitchel Y. B., Paolini J. F., Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clinical Therapeutics 2009 31 1 115 122 2-s2.0-60449103180 10.1016/j.clinthera.2009.01. 010
16. Cleeman J. I., Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001 285 19 2486 2497 2-s2.0-0035897696 (Pubitemid 32433843)
17. Milionis H. J., Liberopoulos E. N., Elisaf M. S., Mikhailidis D. P., Analysis of antihypertensive effects of statins. Current Hypertension Reports 2007 9 3 175 183 2-s2.0-34250202252 10.1007/s11906-007-0032-4 (Pubitemid 46894811)
18. Milionis H. J., Liberopoulos E. N., Achimastos A., Elisaf M. S., Mikhailidis D. P., Statins: another class of antihypertensive agents? Journal of Human Hypertension 2006 20 5 320 335 2-s2.0-33646037997 10.1038/sj.jhh.1002001
19. Reisin E., Ebenezer P. J., Liao J., Lee B. S., Larroque M., Hu X., Aguilar E. A., Morse S. A., Francis J., Effect of the HMG-Coa reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. American Journal of the Medical Sciences 2009 338 4 301 309 2-s2.0-70350146802 10.1097/MAJ.0b013e3181b27195
20. Kostapanos M. S., Milionis H. J., Elisaf M. S., Current role of statins in the treatment of essential hypertension. Expert Opinion on Pharmacotherapy 2010 11 16 2635 2650 10.1517/14656566.2010.491512
21. Barreto A. C., Maeda N. Y., Soares R. P. S., Cícero C., Lopes A. A., Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study. Brazilian Journal of Medical and Biological Research 2008 41 8 657 663 2-s2.0-52949126746
22. Yavuz B., Ertugrul D. T., Cil H., Ata N., Akin K. O., Yalcin A. A., Kucukazman M., Dal K., Hokkaomeroglu M. S., Yavuz B. B., Tutal E., Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovascular Drugs and Therapy 2009 23 4 295 299 2-s2.0-69249232094 10.1007/s10557-009-6181-8
23. Florentin M., Elisaf M. S., Mikhailidis D. P., Vitamin D and metabolic syndrome: is there a link? Current Pharmaceutical Design 2010 16 3417 3434
24. Florentin M., Liberopoulos E. N., Kei A. A., Mikhailidis D. P., Elisaf M. S., Pleiotropic effects of nicotinic acid: beyond High Density Lipoprotein Cholesterol elevation. Current Vascular Pharmacology. In press
25. Kei A. A., Liberopoulos E. N., Elisaf M. S., What restricts nicotinic acid's clinical use? Current Vascular Pharmacology. In press
26. Gadegbeku C. A., Dhandayuthapani A., Shrayyef M. Z., Egan B. M., Hemodynamic effects of nicotinic acid infusion in normotensive and hypertensive subjects. American Journal of Hypertension 2003 16 1 67 71 2-s2.0-0037230621 10.1016/S0895-7061(02)03196-5 (Pubitemid 36078594)
27. Kelly J. J., Lawson J. A., Campbell L. V., Storlien L. H., Jenkins A. B., Whitworth J. A., O'Sullivan A. J., Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. Journal of Human Hypertension 2000 14 9 567 572 2-s2.0-0033812857
28. Canner P. L., Furberg C. D., McGovern M. E., Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). American Journal of Cardiology 2006 97 4 477 479 2-s2.0-31944438344 10.1016/j.amjcard.2005.08.070 (Pubitemid 43190034)
29. Paolini J. F., Mitchel Y. B., Reyes R., Kher U., Lai E., Watson D. J., Norquist J. M., Meehan A. G., Bays H. E., Davidson M., Ballantyne C. M., Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. American Journal of Cardiology 2008 101 5 625 630 2-s2.0-41949100903 10.1016/j.amjcard.2007.10.023 (Pubitemid 351625086)
30. Parhofer K. G., Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vascular Health and Risk Management 2009 5 901 908 2-s2.0-74049112916
31. Florentin M., Liberopoulos E. N., Wierzbicki A. S., Mikhailidis D. P., Multiple actions of high-density lipoprotein. Current Opinion in Cardiology 2008 23 4 370 378 2-s2.0-44649096384 10.1097/HCO.0b013e3283043806 (Pubitemid 351787103)
32. Sorrentino S. A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F. H., Mueller M., Horváth T., Doerries C., Heinemann M., Flemmer S., Markowski A., Manes C., Bahr M. J., Haller H., Von Eckardstein A., Drexler H., Landmesser U., Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010 121 1 110 122 2-s2.0-74549172922 10.1161/CIRCULATIONAHA.108.836346
33. Cooke J. P., Asymmetrical dimethylarginine: the Über marker? Circulation 2004 109 15 1813 1819 2-s2.0-1942438521 10.1161/01.CIR.0000126823. 07732.D5 (Pubitemid 38509112)
34. Westphal S., Borucki K., Luley C., Martens-Lobenhoffer J., Bode-Böger S. M., Treatment with niacin lowers ADMA. Atherosclerosis 2006 184 2 448 450 2-s2.0-30044448790 10.1016/j.atherosclerosis.2005.11.018 (Pubitemid 43049734)